1519.1 - Tisagenlecleucel (CTL019) for treatment of relapsed or refractory diffuse large B-cell lymphoma

Page last updated: 31 May 2019

Application Detail

Status

Open

Description of Medical Service

Tisagenlecleucel is an autologous, murine anti-CD19 Chimeric Antigen Receptor T cell (CAR-T) therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.

Description of Medical Condition

Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive and common subtype of Non-Hodgkin Lymphoma (NHL).

Reason for Application

Re-submission

Medical Service Type

Hybrid health technology

Previous Application Number

1519

Associated Documentation

Application Form

-

Consultation Survey

Feedback and comments are welcome at any stage during the MSAC process. Please provide comments on Application 1519.1 via a maximum of two A4 pages to HTA@health.gov.au (making sure that you type the application number at the start of your comments and in the subject heading of your email).

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

-

ESC

13 June 2019

MSAC

-